Sage Group is attending BioEurope Spring 2023 from 20-23 March 2023! Please click here to setup a call with us in advance or book on the partnering sessions!

Sage’s new client, Kinnov Therapeutics, is a French-based company focused on one of the major unmet global healthcare challenges, addiction. Kinnov has engaged the Sage Group to manage its sale process. On this site, under our listed Kinnov profile, is a nonconfidential presentation on Kinnov’s product, KT-110, for Alcohol Use Disorder (AUD) for which there has been no new treatment in nearly a decade. KT-110 is a game changer in AUD treatment with blockbuster potential. It h

Hatchtech has engaged the Sage Group to manage the sale process for its lead asset Xeglyze®. Xeglyze is a patent protected, single topical 10-minute application prescription product approved by the FDA and ready for market with manufacturing and supply chain through to finished product all in place and ready for launch. A recent independent, peer-reviewed article in the Annals of Pharmacotherapy stated: “The FDA approval of abametapir (Xeglyze) is an important development in